The Science Advisory Board

New immunotherapy piggybacks off polio vaccine to treat cancer
As if we needed another reason to get vaccinated, researchers have developed a technology that leverages the polio vaccine to help treat cancer for those who develop the disease later in life. The technology, conceived at Duke University and developed by Istari Oncology, uses antigens produced by the polio vaccine to trigger the immune system to eat away at targeted cancer cells. Read More

CRISPR phage offers precision medicine tool to fight bacterial infections
In an attempt to combat bacterial infections, Locus Biosciences is developing bacteriophage therapies that deliver CRISPR-Cas3 machinery directly to specific, targeted pathogens to obliterate them. Locus CEO Paul Garofolo discusses the company's technology and recent updates with The ScienceBoard.net. Read More

Effectiveness of COVID-19 vaccines will rely on public trust
No matter how effective upcoming COVID-19 vaccines are, their ultimate success in combating the pandemic will depend on how much the public trusts the safety and efficacy of the products. That's according to a panel of physicians and scientists who discussed COVID-19 vaccine trials in a briefing on October 29. Read More

New methods could improve AAV quality for viral vector manufacturing
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical researchers is trying to overcome this challenge by developing novel analytical methodology specifically designed for AAVs. Read More

Is 'bespoke' therapy the future of genomic medicine?
Gene therapies hold extremely exciting promise for meeting the unmet needs of many individuals with genetic diseases, as discussed in a session of the second annual American Society of Gene & Cell Therapy Policy Summit on September 24. Read More

Science serves society, a crucial concept for gene therapy governance
With a focus on science and society, the American Society of Gene & Cell Therapy Policy Summit commenced on September 24. The ensuing discussion revealed how far science has advanced in a short period of time, and how the scientific community is rising to the challenge of gaining public buy-in for gene therapy. Read More

Celebration of postdocs transitions to virtual platform
For the first time ever, the National Postdoctoral Association will celebrate National Postdoc Appreciation Week from September 21-25 as a virtual, collaborative event among multiple institutions. Executive Director Tom Kimbis discusses how the organization is adapting to meet the challenges of COVID-19 to support and advocate for postdocs. Read More

Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic. Read More

Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of customization, manufacturing expertise, and years' worth of knowledge. Read More

Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune diseases. The company that is developing the platform, Precigen ActoBio, is advancing a lead candidate through clinical trials with the long-term goal of finding a sweet spot between biologics and gene therapies. Read More

« prev 1 2 3 4 next »